The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast
Open Access
- 27 May 2020
- journal article
- research article
- Published by Elsevier BV in Medical Hypotheses
- Vol. 143, 109883
- https://doi.org/10.1016/j.mehy.2020.109883
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Coronaviruses — drug discovery and therapeutic optionsNature Reviews Drug Discovery, 2016
- Inflammatory Cytokines in General and Central Obesity and Modulating Effects of Physical ActivityPLOS ONE, 2015
- ZINC: A Free Tool to Discover Chemistry for BiologyJournal of Chemical Information and Modeling, 2012
- Southall And Brent REvisited: Cohort profile of SABRE, a UK population-based comparison of cardiovascular disease and diabetes in people of European, Indian Asian and African Caribbean originsInternational Journal of Epidemiology, 2010
- Effect of Montelukast on Pro-inflammatory Cytokine Production During Naturally Acquired Viral Upper Respiratory Infections (vURIs) in AdultsJournal of Allergy and Clinical Immunology, 2008
- Cysteinyl leukotrienes: multi‐functional mediators in allergic rhinitisClinical & Experimental Allergy, 2006
- Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parametersInternational Journal of Obesity, 2006
- Cysteinyl Leukotrienes and Their Receptors: Cellular Distribution and Function in Immune and Inflammatory ResponsesThe Journal of Immunology, 2004
- Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to antigen, airway eosinophilia, and IL-5–expressing cells in Brown Norway ratsJournal of Allergy and Clinical Immunology, 1999
- Leukotriene E4 and granulocytic infiltration into asthmatic airwaysThe Lancet, 1993